Chemotherapy for prostate cancer

被引:92
作者
Gilligan, T [1 ]
Kantoff, PW [1 ]
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
关键词
D O I
10.1016/S0090-4295(02)01583-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Androgen deprivation therapy remains the mainstay of therapy for patients with advanced prostate cancer and for selected patients with localized prostate cancer. Androgen deprivation therapy is the model of target-based therapies in this disease. Although it is clear that other target-based therapies need to be developed, cytotoxic chemotherapy is emerging as an effective form of treatment for men with prostate cancer. The early studies combining mitoxantrone plus a corticosteroid demonstrated that chemotherapy could be given to men with symptomatic hormone-refractory prostate cancer with minimal toxicity, and significant palliation could be provided. Since then, it has been recognized that estramustine, when combined with a variety of microtubular inhibitors, is very active in hormone-refractory prostate cancer. Doublets combining estramustine plus a taxane seem to be the most active. Although it appears that estramustine may add some activity to taxanes, the mechanism of its activity is uncertain, and its overall value is similarly questioned, particularly in light of its significant toxicity. Regimens that omit estramustine are being explored (ie, either taxane alone or taxane plus biologic agents). In addition, triplet therapy (combining estramustine plus a taxane plus a third drug, such as carboplatin or etoposide) is being explored. Finally, the utility of chemotherapy is beginning to be explored in the context of earlier disease in the neoadjuvant, adjuvant, or serologically relapsing group of patients. Data from these studies are just beginning to be gathered.
引用
收藏
页码:94 / 100
页数:7
相关论文
共 47 条
  • [1] ATHANASIADIS A, 2001, P AN M AM SOC CLIN, V20, pA189
  • [2] Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer
    Attivissimo, LA
    Fetten, JV
    Kreis, W
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (06): : 581 - 583
  • [3] Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer
    Beer, TM
    Pierce, WC
    Lowe, BA
    Henner, WD
    [J]. ANNALS OF ONCOLOGY, 2001, 12 (09) : 1273 - 1279
  • [4] MECHANISMS OF ACTION AND CLINICAL USES OF ESTRAMUSTINE
    BENSON, R
    HARTLEYASP, B
    [J]. CANCER INVESTIGATION, 1990, 8 (3-4) : 375 - 380
  • [5] BERRY W, 2001, P AN M AM SOC CLIN, V20, pA175
  • [6] CALABRESI P, 1993, GOODMAN GILMANS PHAR, P1241
  • [7] Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer
    Clark, PE
    Peereboom, DM
    Dreicher, R
    Levin, HS
    Clark, SB
    Klein, EA
    [J]. UROLOGY, 2001, 57 (02) : 281 - 285
  • [8] Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer
    Colleoni, M
    Graiff, C
    Vicario, G
    Nelli, P
    Sgarbossa, G
    Pancheri, F
    Manente, P
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1997, 20 (04): : 383 - 386
  • [9] Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer
    Copur, MS
    Ledakis, P
    Lynch, J
    Hauke, R
    Tarantolo, S
    Bolton, M
    Norvell, M
    Muhvic, J
    Hake, L
    Wendt, J
    [J]. SEMINARS IN ONCOLOGY, 2001, 28 (04) : 16 - 21
  • [10] Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: A decade of progress?
    Culine, S
    Droz, JP
    [J]. ANNALS OF ONCOLOGY, 2000, 11 (12) : 1523 - 1530